Eli Lilly Explores New R&D Cooperation Model In
This article was originally published in PharmAsia News
Eli Lilly, one of the first international drug companies to develop large-scale R&D activities in China, continues to explore new R&D cooperation models aimed at enhancing partnerships
You may also be interested in...
The European Medicines Agency’s clinical data publication policy is on hold, but calls are growing for the regulator to start publishing trial data for COVID-19 treatments and vaccines as soon as they are authorized in the EU.
Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.